However, the treatment effectiveness of FLT3 inhibitors is often limited by the development of resistance.[27] Even though CDK6 is a downstream target of FLT3, it also controls the FLT3 signaling pathways by binding directly to the FLT3 promoter site.[26] This noxious cycle promotes leukemia cell proliferation and survival, making it a critical target for therapeutic intervention. The gene discussed is CDK6; the disease is leukemia.